Daxor Corporation (DXR)

[surf1944]

8:32AM Daxor Corporation announces a study on the significant diagnostic benefits to congestive heart failure patients utilizing the Daxor BVA-100 Blood Volume Analyzer (DXR) 7.23 : A study utilizing blood volume measurement from College of Physicians & Surgeons at Columbia University was published in the October 2013 issue of the Journal of Cardiac Failure. The study involved measurement of blood volume utilizing the Daxor BVA-100 Blood Volume Analyzer on patients diagnosed with congestive heart failure and treated with Erythropoietin stimulating agents (ESAs). The study was sponsored by the National Institutes of Health and the New York Academy of Medicine. It has been previously noted that some patients do not respond to the ESA drug and may actually have higher complications. They are called hyporesponders. In contrast, another group of heart failure patients do respond with increased red blood cells and improved symptoms to the same drug. They are termed responders. The study found that the patients who were responders were patients who did not have an enlarged blood volume and had a true anemia. In contrast, the patients who were determined to be hyporesponders had significantly enlarged blood volumes due to their plasma volume enlargement. In effect, the red blood cells which traveled with the plasma in the circulation are diluted by the expanded plasma or water part of the blood volume. The result of this is that these patients who do not respond well to ESA stimulants have, in effect, a false or pseudo anemia